Societal costs of ovarian cancer in a population-based cohort - a cost of illness analysis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Dahm Kähler Pernilla 1964) > (2020-2024) > Societal costs of o...

Palmqvist, CharlotteGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology (författare)

Societal costs of ovarian cancer in a population-based cohort - a cost of illness analysis

Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

2022-11-03
Informa UK Limited,2022

Nummerbeteckningar

LIBRIS-ID:oai:gup.ub.gu.se/320501
https://gup.ub.gu.se/publication/320501URI
https://doi.org/10.1080/0284186x.2022.2140015DOI

Kompletterande språkuppgifter

Språk:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Background The societal cost associated with ovarian cancer (OC) is not well known. Increasing costs for new treatments and/or the impact of organizational changes motivates these costs to be described and communicated. This study aims to evaluate the cost of illness of OC in a population-based cohort. Material and methods All patients diagnosed with ovarian, fallopian tube, primary peritoneal cancer, and serous cancer of undesignated primary site (UPS) in 2011-2012 were followed for six years. Direct costs, i.e., costs for health care expenditures, were gathered from the regional healthcare database. Information on indirect costs, i.e., costs of loss of production due to sick leave, was retrieved from Statistics Sweden. Sub-group analyses were conducted regarding stage, income levels, residential area, and diagnosis. Results The cost of illness for all stages during the six years of follow-up was euro201,086 per patient, where indirect costs constituted 43.7%. The mean cost of illness per year per patient for all stages was euro33,514. Direct costs were higher in advanced stages compared to early stages for every year from diagnosis. During the first two years, there were no differences in indirect costs between early and advanced stages. However, during the third year there was a difference with higher indirect costs in advanced stages. There was no difference in direct costs depending on income levels. Regarding residential area, there was a difference in the outpatient cost during the index and second year with higher costs when chemotherapy and follow-up were provided at county hospitals, compared to at the tertiary hospital. Conclusions Indirect costs constituted a large part of the cost of illness over 6 years from diagnosis. This could indicate that even though treatment costs can be expected to rise with the introduction of new therapies, the societal cost may decrease when survival increase.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
Cost of illness
direct cost
indirect cost
societal cost
ovarian
cancer
maintenance therapy
complete cytoreduction
niraparib maintenance
parp
inhibitors
survival
disparities
bevacizumab
guidelines
adherence
olaparib
Oncology

Biuppslag (personer, institutioner, konferenser, titlar ...)

Persson, Josefine,1981Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine(Swepub:gu)xpejos (författare)
Albertsson, Per,1964Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xalbpe (författare)
Dahm-Kähler, Pernilla,1964Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology(Swepub:gu)xdahmp (författare)
Johansson, Mia,1977Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xjmiaa (författare)
Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi (creator_code:org_t)

Sammanhörande titlar

Ingår i:Acta Oncologica: Informa UK Limited61:11, s. 1369-13760284-186X1651-226X

Internetlänk

Hitta via bibliotek

Acta Oncologica (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Palmqvist, Charl ...; Persson, Josefin ...; Albertsson, Per, ...; Dahm-Kähler, Per ...; Johansson, Mia, ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Acta Oncologica

Av lärosätet: Göteborgs universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se